Mylan, Famy Care agree to develop oral contraceptives for U.S. market

PITTSBURGH Mylan will develop and supply 22 oral contraceptive medicines to American customers under an agreement with Mumbai, India-based women’s health-care products manufacturer Famy Care, Mylan announced Wednesday.

The two companies did not disclose the terms of the agreement, but it does give Mylan a right of first refusal for additional markets in which the Pittsburgh-based generic drug manufacturer operates, such as Australia and Japan.

Mylan expects to begin filing applications for new drugs in the next few months and commercializing them by 2010, Chairman and chief executive officer Robert Coury said.

“Through our partnership with Famy Care, we have met another longstanding commitment by expanding our portfolio to create a women’s health-care franchise for Mylan,” he said.

Market sales for oral contraceptives in the United States are about $3.3 billion, according to IMS data.